Chen Cai-Ping, Chen Xin, Qiao Yan-Ning, Wang Pei, He Wei-Qi, Zhang Cheng-Hai, Zhao Wei, Gao Yun-Qian, Chen Chen, Tao Tao, Sun Jie, Wang Ye, Gao Ning, Kamm Kristine E, Stull James T, Zhu Min-Sheng
Model Animal Research Center and MOE Key Laboratory of Animal Models of Disease, Nanjing University, Nanjing, China.
J Physiol. 2015 Feb 1;593(3):681-700. doi: 10.1113/jphysiol.2014.283853. Epub 2014 Dec 23.
Force production and maintenance in smooth muscle is largely controlled by myosin regulatory light chain (RLC) phosphorylation, which relies on a balance between Ca(2+)/calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP) activities. MYPT1 is the regulatory subunit of MLCP that biochemically inhibits MLCP activity via T694 or T852 phosphorylation in vitro. Here we separately investigated the contribution of these two phosphorylation sites in bladder smooth muscles by establishing two single point mutation mouse lines, T694A and T852A, and found that phosphorylation of MYPT1 T694, but not T852, mediates force maintenance via inhibition of MLCP activity and enhancement of RLC phosphorylation in vivo. Our findings reveal the role of MYPT1 T694/T852 phosphorylation in vivo in regulation of smooth muscle contraction.
Force production and maintenance in smooth muscle is largely controlled by different signalling modules that fine tune myosin regulatory light chain (RLC) phosphorylation, which relies on a balance between Ca(2+)/calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP) activities. To investigate the regulation of MLCP activity in vivo, we analysed the role of two phosphorylation sites on MYPT1 (regulatory subunit of MLCP) that biochemically inhibit MLCP activity in vitro. MYPT1 is constitutively phosphorylated at T694 by unidentified kinases in vivo, whereas the T852 site is phosphorylated by RhoA-associated protein kinase (ROCK). We established two mouse lines with alanine substitution of T694 or T852. Isolated bladder smooth muscle from T852A mice displayed no significant changes in RLC phosphorylation or force responses, but force was inhibited with a ROCK inhibitor. In contrast, smooth muscles containing the T694A mutation showed a significant reduction of force along with reduced RLC phosphorylation. The contractile responses of T694A mutant smooth muscle were also independent of ROCK activation. Thus, phosphorylation of MYPT1 T694, but not T852, is a primary mechanism contributing to inhibition of MLCP activity and enhancement of RLC phosphorylation in vivo. The constitutive phosphorylation of MYPT1 T694 may provide a mechanism for regulating force maintenance of smooth muscle.
平滑肌中的力产生和维持在很大程度上受肌球蛋白调节轻链(RLC)磷酸化控制,这依赖于钙(2+)/钙调蛋白依赖性肌球蛋白轻链激酶(MLCK)和肌球蛋白轻链磷酸酶(MLCP)活性之间的平衡。MYPT1是MLCP的调节亚基,在体外通过T694或T852磷酸化在生化水平上抑制MLCP活性。在这里,我们通过建立两个单点突变小鼠品系T694A和T852A,分别研究了这两个磷酸化位点在膀胱平滑肌中的作用,发现MYPT1的T694而非T852的磷酸化通过在体内抑制MLCP活性和增强RLC磷酸化来介导力的维持。我们的研究结果揭示了MYPT1 T694/T852磷酸化在体内对平滑肌收缩调节中的作用。
平滑肌中的力产生和维持在很大程度上受不同信号模块控制,这些模块微调肌球蛋白调节轻链(RLC)磷酸化,而RLC磷酸化依赖于钙(2+)/钙调蛋白依赖性肌球蛋白轻链激酶(MLCK)和肌球蛋白轻链磷酸酶(MLCP)活性之间的平衡。为了研究体内MLCP活性的调节,我们分析了MYPT1(MLCP的调节亚基)上两个在体外生化水平上抑制MLCP活性的磷酸化位点的作用。在体内,MYPT1的T694被未知激酶组成性磷酸化,而T852位点由RhoA相关蛋白激酶(ROCK)磷酸化。我们建立了两个T694或T852被丙氨酸取代的小鼠品系。来自T852A小鼠的分离膀胱平滑肌在RLC磷酸化或力反应方面没有显著变化,但力被ROCK抑制剂抑制。相比之下,含有T694A突变的平滑肌显示力显著降低,同时RLC磷酸化减少。T694A突变平滑肌的收缩反应也独立于ROCK激活。因此,MYPT1的T694而非T852的磷酸化是在体内抑制MLCP活性和增强RLC磷酸化的主要机制。MYPT1 T694的组成性磷酸化可能为调节平滑肌的力维持提供一种机制。